IRF5 and type 1 diabetes mellitus: This opens the door to consider glucose-lowering agents such as the DPP4 inhibitors as tools to intervene in the interaction of COVD-19, dysglycemic states and the HBP-GlcNAc-OGT–IRF5-interferon pathway, keeping in mind that DPP-4 inhibitors are not indicated in T1D individuals (50).